Imprimis Pharmaceuticals Sells Pennsylvania Facility and Sinus Assets

Industry Reports
Typography

Imprimis Pharmaceuticals, Inc , an ophthalmology-focused pharmaceutical company, announced it has entered into an agreement to sell its Folcroft, Pennsylvania facility and sinus related assets for $450,000.  

The closing of this transaction is expected to occur on or around July 17, 2017, subject to customary terms and conditions. 

Mark L. Baum, CEO of Imprimis said, "We are committed to focusing on our core growing ophthalmology business.  The markets we serve with proprietary products in ophthalmology, including our cataract surgery portfolio, medications used in post-LASIK surgery care, our Simple Drops glaucoma program we recently launched and the upcoming launches we have planned to serve dry eye disease patients and other markets in ophthalmology should allow us to build a profitable and valuable company."  Baum continued, "In furtherance of this focus, we entered into an agreement to sell our Folcroft facility and exit the sinus space.  We believe this is an important step towards reducing non-strategic overhead expenses and focusing internal resources on strengthening our growing ophthalmology business."

About Imprimis Pharmaceuticals
Imprimis Pharmaceuticals, Inc. is a pharmaceutical company dedicated to producing and dispensing high quality innovative medications in all 50 states.  The company's unique business model increases patient access and affordability to many critical medicines.  Headquartered in San Diego, California, Imprimis owns and operates three production and dispensing facilities located in California, New Jersey and Pennsylvania. For more information about Imprimis, please visit the corporate website at www.ImprimisRx.com. 

Investor Contact:
Andrew Boll
This email address is being protected from spambots. You need JavaScript enabled to view it.
858-704-4042

Sign up via our free email subscription service to receive notifications when new information is available.
captcha 

Market Movers

Rogers Corporation

NYQ : ROG - 16 Oct, 4:02pm
139.53
+2.83 (+2.07%) After Hours:
Open 137.60 Mktcap 2.54B
High 139.74 52wk Hight 139.74
Low 137.05 52wk Low 51.98
Vol 86121 Avg Vol 120528
Eps 5.55 P/e 33.70
Currency: USD

Banco Santander, S.A. Sponsored

NYQ : SAN - 16 Oct, 4:04pm
6.52
-0.01 (-0.11%) After Hours:
Open 6.51 Mktcap 20.57B
High 6.53 52wk Hight 6.99
Low 6.47 52wk Low 4.36
Vol 3.84M Avg Vol 5.41M
Eps 0.49 P/e 11.99
Currency: USD

Merck & Company, Inc. (new)

NYQ : MRK - 16 Oct, 4:00pm
63.34
-0.05 (-0.08%) After Hours:
Open 63.49 Mktcap 172.75B
High 63.73 52wk Hight 66.80
Low 63.26 52wk Low 58.29
Vol 7.45M Avg Vol 7.72M
Eps 3.87 P/e 34.24
Currency: USD

Johnson & Johnson

NYQ : JNJ - 16 Oct, 4:00pm
136.12
-0.31 (-0.23%) After Hours:
Open 136.45 Mktcap 365.35B
High 137.26 52wk Hight 137.52
Low 135.54 52wk Low 109.32
Vol 5.12M Avg Vol 5.26M
Eps 7.18 P/e 22.88
Currency: USD

Pfizer, Inc.

NYQ : PFE - 16 Oct, 4:00pm
35.98
-0.36 (-0.99%) After Hours:
Open 36.35 Mktcap 59.45B
High 36.48 52wk Hight 36.60
Low 35.88 52wk Low 29.83
Vol 13.58M Avg Vol 17.16M
Eps 2.56 P/e 26.26
Currency: USD

Direxion Daily 10-Yr Treasury B

PCX : TYO - 16 Oct, 3:37pm
13.81
+0.06 (+0.44%) After Hours:
Open Mktcap
High 52wk Hight 16.29
Low 52wk Low 13.12
Vol 0 Avg Vol 3888
Eps P/e
Currency: USD